Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 21642681)

1.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
2.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Nov 2;306(17):1865-73. doi: 10.1001/jama.2011.1591. Epub 2011 Oct 26.

PMID:
22031728
3.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team.

Am J Obstet Gynecol. 2005 Nov;193(5):1630-9. Erratum in: Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

PMID:
16260202
4.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

5.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

6.

Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.

Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.

Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.

PMID:
23065684
7.

Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE.

Ann Fam Med. 2009 May-Jun;7(3):212-22. doi: 10.1370/afm.942.

8.

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I.

Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.

9.

Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.

10.

Abnormal CA-125 levels in menopausal women without ovarian cancer.

Terada KY, Elia J, Kim R, Carney M, Ahn HJ.

Gynecol Oncol. 2014 Oct;135(1):34-7. doi: 10.1016/j.ygyno.2014.08.008. Epub 2014 Aug 13.

PMID:
25127988
11.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
12.

Results from four rounds of ovarian cancer screening in a randomized trial.

Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS; PLCO Project Team.

Obstet Gynecol. 2009 Apr;113(4):775-82. doi: 10.1097/AOG.0b013e31819cda77.

13.

Ovarian cancer screening in women with a family history of breast or ovarian cancer.

Lacey JV Jr, Greene MH, Buys SS, Reding D, Riley TL, Berg CD, Fagerstrom RM, Hartge P.

Obstet Gynecol. 2006 Nov;108(5):1176-84.

PMID:
17077240
14.

Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis.

Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L.

Gynecol Oncol. 2013 Sep;130(3):674-81. doi: 10.1016/j.ygyno.2013.06.029. Epub 2013 Jun 30. Review.

PMID:
23822892
15.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683
16.

Screening for ovarian cancer: a pilot randomised controlled trial.

Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH.

Lancet. 1999 Apr 10;353(9160):1207-10.

PMID:
10217079
17.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S.

PMID:
11189684
18.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; PLCO Project Team.

N Engl J Med. 2012 Jun 21;366(25):2345-57. doi: 10.1056/NEJMoa1114635. Epub 2012 May 21.

19.

Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.

Partridge EE, Greenlee RT, Riley TL, Commins J, Ragard L, Xu JL, Buys SS, Prorok PC, Fouad MN.

Obstet Gynecol. 2013 Jan;121(1):25-31. doi: http://10.1097/AOG.0b013e3182755e14.

20.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126. Epub 2010 May 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk